Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 2018 | Supplemental Material + Published
Journal Article Open

Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation

Abstract

Late in the HIV-1 replication cycle, the viral structural protein Gag is targeted to virus assembly sites at the plasma membrane of infected cells. The capsid (CA) domain of Gag plays a critical role in the formation of the hexameric Gag lattice in the immature virion, and, during particle release, CA is cleaved from the Gag precursor by the viral protease and forms the conical core of the mature virion. A highly conserved Pro-Pro-Ile-Pro (PPIP) motif (CA residues 122 to 125) [PPIP(122–125)] in a loop connecting CA helices 6 and 7 resides at a 3-fold axis formed by neighboring hexamers in the immature Gag lattice. In this study, we characterized the role of this PPIP(122–125) loop in HIV-1 assembly and maturation. While mutations P123A and P125A were relatively well tolerated, mutation of P122 and I124 significantly impaired virus release, caused Gag processing defects, and abolished infectivity. X-ray crystallography indicated that the P122A and I124A mutations induce subtle changes in the structure of the mature CA lattice which were permissive for in vitro assembly of CA tubes. Transmission electron microscopy and cryo-electron tomography demonstrated that the P122A and I124A mutations induce severe structural defects in the immature Gag lattice and abrogate conical core formation. Propagation of the P122A and I124A mutants in T-cell lines led to the selection of compensatory mutations within CA. Our findings demonstrate that the CA PPIP(122–125) loop comprises a structural element critical for the formation of the immature Gag lattice.

Additional Information

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply. Received 18 July 2018; Accepted 12; September 2018; Published 16 October 2018. We thank members of the Freed laboratory for helpful discussion and critical review of the manuscript. This work was supported by the Intramural Research Programs of the Center for Cancer Research, National Cancer Institute, NIH (E.O.F.), and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (A.C.S.); by the Intramural AIDS Targeted Antiviral Program (E.O.F. and A.C.S.), National Institute of Allergy and Infectious Diseases (R01-AI120860, R21-AI112417, and U54 GM103368), NIH (S.G.S.); and by the University of Leeds (University Academic Fellow scheme; J.F.). This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN26120080001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Attached Files

Published - e01567-18.full.pdf

Supplemental Material - inline-supplementary-material-1.pdf

Files

inline-supplementary-material-1.pdf
Files (3.6 MB)
Name Size Download all
md5:3ca247870c6ca77cdc30c5ae94be4788
92.7 kB Preview Download
md5:a253b8bff9628200d07118da0f49e75a
3.5 MB Preview Download

Additional details

Created:
August 21, 2023
Modified:
October 18, 2023